Featured news from NHIVNA
HIV-related news from NAM
Long-acting injectable drugs work well for HIV maintenance therapy
Liz Highleyman, 2016-07-22 08:10:00
Two long-acting injectable
antiretrovirals – cabotegravir and rilpivirine – administered once every 4 or 8
weeks maintained viral suppression in people who switched regimens with
undetectable viral load, according to 48-week results from the LATTE-2 trial
presented yesterday at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa. A related
qualitative analysis showed that study participants preferred long-acting injectables over pills for several
Consistent good adherence is the
key to successful HIV treatment, and long-acting injectable medications could
offer an attractive option for people facing a lifetime of antiretroviral therapy
(ART). The drawback is that these drugs cannot be removed from the body if side
David Margolis of ViiV Healthcare presented findings
from the international LATTE-2 trial, which evaluated a maintenance regimen
consisting of injectable formulations of ViiV's experimental integrase cabotegravir and the approved
NNRTI rilpivirine (oral formulation marketed as Edurant, also in Eviplera or Complera).
To ensure the basic efficacy and safety of these drugs
before testing the injectable formulations in humans, the initial LATTE-1 (Long-Acting Antiretroviral Treatment Enabling) trial
evaluated oral cabotegravir plus rilpivirine as a simplified two-drug maintenance regimen for people who had achieved
undetectable viral load using standard three-drug ART.
In 2014 Dr Margolis presented 48-week findings showing
that 82% of participants who switched to oral cabotegravir plus rilpivirine
maintained viral suppression, compared to 71% of those who stayed on a
three-drug regimen containing efavirenz (Sustiva). At 96 weeks the corresponding response rates were 76% and
73%, respectively. The oral combination was found to be safe and
These promising results laid the groundwork for
testing the long-acting injectable formulations in the phase 2b
proof-of-concept LATTE-2 trial.
This open-label study enrolled
309 participants previously untreated for HIV. They first started a three-drug
induction regimen of 30mg oral cabotegravir plus abacavir/lamivudine (the drugs
in Kivexa or Epzicom).
Those with viral suppression
(<50 copies/ml) at 20 weeks were randomly assigned to either stay on the
same oral regimen or switch to long-acting cabotegravir and rilpivirine administered
as intramuscular injections in the
buttocks. One group received 400mg cabotegravir plus 600mg rilpivirine administered
every 4 weeks (Q4W) and another received 600mg cabotegravir plus 900mg rilpivirine given
every 8 weeks (Q4W)
Of the 286 participants who
achieved viral suppression during the induction period and were randomised, more
than 90% were men, most were white and the median age was 35 years. At baseline
the median CD4 count was 489 cells/mm3 and 18% had high viral load (>100,000 copies/ml).
At 48 weeks after randomisation, 92% of patients who switched
to the injectables given every 8 weeks and 91% of those treated every 4 weeks
maintained undetectable viral load, as did 89% of those who stayed on the oral
More participants in the Q8W injectable arm
experienced virological non-response compared to those in the Q4W injectable
and oral arms (7%, <1% and 2%, respectively). But more people in the latter
arms had missing data, so overall response rates were similar.
Two participants in the Q8W injectable arm and one in
the oral arm had protocol-defined virological failure at 48 weeks, which
combined criteria for early response and viral rebound. Dr Margolis
noted that by now all participants have been followed through 72 weeks with no
further protocol-defined failures.
The patient with failure in the Q8W arm was thought to
have received an inadequate dose of rilpivirine due to an incorrect injection
and developed emergent NNRTI resistance (K103N, E138G, K238T) and integrase resistance (Q148R) mutations.
Injectable cabotegravir and rilpivirine were generally
safe and well tolerated, with no drug-related serious adverse events; 2% in the
Q8W arm, 6% in the Q4W arm and 2% in the oral arm discontinued due to adverse events.
Other than injection site reactions, the most frequently reported adverse
events were fever, fatigue, flu-like illness, headache and rash, reported by 4%
or fewer participants.
Most people in the injectable arms had injection site
reactions, but these were usually mild (82%) or moderate (17%), and 90%
resolved within a week. The most common reaction was pain (67%), but 7%
developed nodules and 6% had swelling. Nevertheless, less than 1% withdrew from
the study for this reason.
Both Q8W and
Q4W week injections maintained cabotegravir levels similar to those seen with
oral dosing and neither was clearly better in terms of tolerability. Monthly
dosing resulted in a modestly lower rate of virological non-response and was
selected for phase 3 studies planned for later this year. But Dr Margolis said evaluation of both doses will
continue through 96 weeks in LATTE-2 and every-other-month dosing may still be